An 8‐week,randomized, controlled,clinical study of the use of a 0.1% chlorhexidine mouthwash by chronic periodontitis patients

Aim: To evaluate the efficacy of a 2‐week administration of a 0.1% chlorhexidine mouthwash in the short‐term treatment of chronic periodontitis patients and the impact of this product when administered twice by pocket irrigation. Methods: Sixty patients were enrolled in a single‐centre, placebo‐controlled, randomized study with the blind allocation of product to two parallel groups. Clinical assessments were performed, and samples from six selected subgingival sites were collected for microbial analysis by culture at baseline, D15 and D56. Three of the six sites were randomly selected and were treated by subgingival irrigation with the same 0.1% chlorhexidine product at D0 and D7. A subsequent statistical analysis was performed using the paired Student’s t‐test and Wilcoxon rank sum test for within‐group analyses; analysis of variance and the Kruskall–Wallis test were used for between‐group analyses. Results: Two‐week treatment with a 0.1% chlorhexidine mouthwash slightly reduced the gingival inflammation associated with periodontitis. We observed a significant decrease in Gram‐negative, facultative anaerobes and micro‐aerophiles, and a significant increase in Gram‐positive cocci. No increase in the treatment effect was demonstrated by irrigation of the periodontal pockets. Conclusion: The 0.1% chlorhexidine mouthwash showed limited beneficial effects in the treatment of periodontitis patients.     

New mouthwash: an efficacious intervention for oral ulceration associated with Behçet's disease

Topical interventions to treat oral ulcers in Behçet's disease (BD) are crucial to control disease activity and improve patients’ quality of life. Our aim was to evaluate the effectiveness of a new BD mouthwash (BD MW) for oral ulceration. A retrospective cross-sectional study was carried out on 261 BD patients (141 women, mean (SD) age 39.9 (11.8) years, and 120 men, mean (SD) age 41.141(3.7) years). All were assessed using the oral ulcer severity score (OUSS), oral health quality of life (OHQoL), and the Behçet's disease current activity form (BDCAF). Patients were divided into three groups: one group used the BD MW, one group used a betamethasone mouthwash, and the other used no therapeutic mouthwash. Patients were assessed at three and six months. The OUSS in those using the BD MW was nine times lower than it was in those using betamethasone mouthwash (p = 0.001), and 12 times lower than it was in the no mouthwash group (p = 0.001). Compared with the baseline data, use of the BD MW during the first three months significantly reduced the OUSS, the BDCAF score, and intraoral scarring, and also improved OHQoL (p = 0.001, 0.019, 0.012, and 0.001, respectively). Ongoing use of the BD MW after six months significantly improved the OUSS, OHQoL, and intraoral scars, and kept oral and systemic disease activity under control. A total of 20/31 patients reported high levels of satisfaction with its use, and a patients’ satisfaction score showed a preference for it. This study confirms the efficacy of the BD MW in patients with recurrent oral ulceration (ROU). It is more efficacious than betamethasone mouthwash used alone.     

Toxic optic neuropathy: An unusual cause

A 60-year-old woman with a history of chronic alcoholism and tobacco use presented with the complaint of a painless decrease in vision in both eyes. She lost vision first in the left eye then in the right eye. She admitted consuming at least one 16 ounce bottle of over the counter mouthwash daily and denied consumption of any other alcohols, methanol, or antifreeze. She stated that her vision had been continuing to deteriorate in both eyes. Her best-corrected visual acuity was 4/200 in each eye. Color vision was nil in each eye. Her pupils were sluggish bilaterally, and her optic discs were flat and hyperemic with peripapillary hemorrhages. Her visual fields revealed central scotomas bilaterally. The magnetic resonance imaging of the brain and lumbar puncture were within normal limits. Antinuclear antibody, human leukocyte antigen-B27 genotyping, and B12 were normal; serum thiamine was low. While continuing to ingest mouthwash, her vision decreased to count fingers at 2 feet, and maculopapillary bundle pallor developed. She was started on folate and thiamine supplementation. Once she discontinued mouthwash, her vision improved to 20/400 bilaterally, and her central scotomas improved. This case demonstrates an alcohol-induced toxic optic neuropathy from mouthwash ingestion with some visual recovery after discontinuation of the offending agent.     

Antifungal activity of lawsone methyl ether in comparison with chlorhexidine

J Oral Pathol Med (2011) 40 : 90–96 Objective: The aim of this study was to determine the antifungal activity of lawsone methyl ether mouthwash (LME) in comparison with chlorhexidine mouthwash (CHX) in vitro and in vivo. Materials and methods: For in vitro study, each mouthwash preparation was added into the inoculum of Candida. The turbidity was recorded after incubation at 37°C for 48 h. Candidal culture was performed and the number of colony of Candida albicans was recorded. For in vivo study, a crossover clinical trial was conducted in 22 HIV‐infected subjects and 32 denture wearers. Clinical examination was performed and oral rinse technique was carried out immediately before and 0, 1, 2 h after using each mouthwash. Allergy and subjective assessment of the mouthwashes were recorded. Statistical analysis was performed using one‐way ANOVA and linear mixed effect modeling. Results: In vitro, antifungal activity of 0.25% LME was significantly greater than that of 0.12% CHX (P < 0.05) and comparable with that of 0.2% CHX. In vivo, antifungal activity up to 2 hours of 0.025% LME mouthwash was evidenced in both groups of subjects, although significantly lower than that of 0.12% CHX. No allergic reaction was reported. LME mouthwash was graded to have less bitter taste than that of CHX. Subjects’ satisfaction on taste and smell of LME mouthwash was significantly greater than that of CHX (P < 0.05). Conclusions: Lawsone methyl ether mouthwash possesses potent antifungal activity both in vitro and in vivo. However, concentration of the mouthwash needs to be adjusted in addition to further clinical trials on long‐term use.     

医用漱口水治疗糖尿病病人慢性牙周炎效果观察

目的观察医用漱口水对糖尿病病人慢性牙周炎的治疗效果。方法将156例2型糖尿病并发慢性牙周炎病人随机分为2组,对照组采用基础治疗,实验组在基础治疗基础上加漱口水治疗,观察治疗前后病人牙周指标的变化。结果两组病人治疗前菌斑指数（PLI）、牙周探针深度（PD）、附着水平丧失（AL）、牙齿松动度（TM）均无明显差异（P〉0．05）。两组病人治疗后PD、AL、TM比较差异有显著性（t=3．498～6．842,P〈0．01）。结论医用漱口水可以明显改善糖尿病病人牙周基础治疗后的疗效。     

A rapid non-invasive method for the detection of the haemochromatosis C282Y mutation

We describe the rapid single-step detection, by mutagenically separated polymerase chain reaction (MS-PCR), of the HLE C282Y mutation, for which > 90% of haemochromatosis patients in the U.K. are homozygous. In addition to using purified DNA as a template, whole blood and lysed buccal cell extracts from mouthwash samples can be used. Therefore sample collection may be non-invasive and purification steps kept to a minimum.     

乌针漱口液口腔护理预防ICU患者呼吸机相关性肺炎的效果观察

摘要：目的 观察乌针漱口液口腔护理预防ICU患者呼吸机相关性肺炎（VAP）的防治效果。方法 选取2019年4月至2020年6月在广西中医药大学附属瑞康医院ICU收治的92例经口气管插管机械通气治疗的患者,采用随机数字法分为观察组和对照组,每组46例。观察组采用乌针漱口液进行口腔护理,对照组采用生理盐水进行口腔护理,比较两组患者护理后的临床肺部感染评分(CPIS)、机械通气时间、口腔评估指南（0AG）评分、口咽及气管内定植菌发生率、VAP发生率、满意度的情况。结果 护理后,观察组的CPIS评分、机械通气时间均明显低于对照组,差异有统计学意义(P＜0.05);观察组的口腔黏膜、牙龈、唾液、口腔异味、吞咽功能和0AG总分明显均优于对照组,差异有统计学意义(P＜0.05);观察组的口咽及气管内定植菌发生率、VAP发生率均明显低于对照组,差异有统计学意义(P＜0.05);观察组口满意度明显高于对照组,差异有统计学意义(P＜0.05)。结论 乌针漱口液口腔护理能更好地降低ICU机械通气患者VAP的发生率,减少机械通气时间,改善口腔健康情况,患者满意度较高。     

解毒愈疡漱口方用于防治急性白血病化疗相关口腔黏膜炎的研究

[目的]探讨解毒愈疡漱口方对急性白血病化疗并发口腔黏膜炎的临床疗效。[方法]随机入组90例急性白血病接受联合化疗患者,治疗组45例,予解毒愈疡漱口方漱口；对照组给45例,予康复新液漱口。观察治疗组与对照组在化疗第5天、第10天的口腔黏膜炎疗效,以及对血常规、肝肾功能的影响。[结果]化疗第5天治疗组与对照组口腔黏膜炎发生率及严重程度无明显统计学差异,而化疗第10天治疗组较对照组口腔黏膜炎程度及疼痛程度明显减轻,具有统计学差异(p＜0.05)。两组血常规、肝肾功能无统计学差异(p＞0.05)。[结论]中药解毒愈疡漱口方含服漱口对防治口腔黏膜炎有效率、创面愈合率疗效显著,且消肿止痛效果明显,大大提高了病人的舒适度及满意度。